Cardiology is entering another period of rapid change, with major clinical trials reshaping treatment across cardiovascular medicine. From research illustrating the expanding cardiovascular benefits of GLP-1 receptor agonists to new evidence linking atrial fibrillation and ATTR-CM, recent studies are demonstrating that the future of patient care will be driven not by promise alone, but by robust clinical evidence. The failure of Wainua in a Phase III trial is a clear example, reinforcing the current ATTR-CM treatment pathway and strengthening the case for established therapies, such as BridgeBio’s Attruby.
Wainua results cement Attruby as the favoured treatment in ATTR-CM
Few cardiology studies have attracted as much attention this year as AstraZeneca’s Phase III Wainua trial in transthyretin amyloid cardiomyopathy (ATTR-CM). Expectations were high that adding Wainua to transthyretin stabilizer therapy would further improve outcomes for patients living with this progressive and life-limiting disease. Instead, the trial failed to meet its primary endpoint, showing no statistically significant reduction in cardiovascular death or recurrent cardiovascular events when Wainua was added to standard care.
The study enrolled 1,432 patients over 140 weeks, but more than half (57%) were already receiving transthyretin stabilizers at enrollment, with a further 24% starting one during the trial. Analysts suggested this made it difficult to demonstrate any incremental benefit from Wainua on top of existing therapies, ultimately raising questions about whether the study design masked the drug’s potential rather than definitively ruling it out.
Rather than reshaping the treatment landscape, the results reinforce the strength of the existing standard of care. With no demonstrated benefit from adding Wainua on top of stabilizer therapy, the findings strengthen the case for BridgeBio’s Attruby as the favored treatment for ATTR-CM.
Exploratory subgroup analyses suggested Wainua may have potential as a monotherapy, but those findings were not sufficient to outweigh the trial’s failure to meet its primary endpoint. The study is, therefore, likely to be remembered less for opening a new treatment pathway than for validating the current one, leaving established stabilizer therapies backed by the strongest body of clinical evidence.
GLP-1 therapies are becoming hard to ignore in cardiovascular prevention
If Wainua reinforced the value of established ATTR-CM therapies, GLP-1 receptor agonists show where cardiovascular prevention may be heading next.
Once viewed mainly as diabetes and obesity medicines, GLP-1 therapies are now building a credible cardiovascular case. New research presented at the American Diabetes Association Scientific Sessions and published in the Journal of the American Heart Association found that adults with obesity and autoimmune disease taking a GLP-1 receptor agonist had a 17% lower risk of venous thromboembolism, a 31% lower risk of pulmonary embolism, a 21% lower likelihood of emergency department visits and a 44% lower risk of death compared with those not receiving the treatment. The analysis also found a modest 13% reduction in stroke risk, although the observed 14% reduction in heart attack risk was not statistically significant.
The evidence still needs to be interpreted carefully as the data itself is observational and does not prove causation. Even so, it fits a broader pattern suggesting that GLP-1 therapies may reduce cardiovascular risk through more than weight loss alone, including improved glycemic control and lower systemic inflammation.
The direction of travel is clear. GLP-1 receptor agonists are moving from metabolic therapy toward a serious role in cardiovascular risk reduction for selected high-risk patients.
CHAMPION-AF is a useful check on enthusiasm for early ablation
CHAMPION-AF evaluated the WATCHMAN FLX left atrial appendage closure device against non-vitamin K oral anticoagulants (NOACs) as a first-line option for stroke risk reduction in patients with non-valvular atrial fibrillation. Its message is simple but important. Attractive treatment strategies still need to prove they improve hard outcomes.
The trial compared the WATCHMAN FLX device with blood-thinning medication in patients with atrial fibrillation. While patients receiving the device experienced fewer bleeding complications over three years, they also had more serious cardiovascular events overall, with 81 events compared with 65 in the medication group. The findings suggest the device is not yet compelling enough to replace current first-line treatment.
In that sense, CHAMPION-AF is not a setback so much as a boundary marker. It helps define where ablation is supported today and where stronger evidence is still needed before practice should change.
The strongest cardiovascular story is still the one proven by evidence
These studies point to a field becoming more selective, and arguably more confident, about what counts as real progress. GLP-1 therapies are forcing cardiology to think more seriously about prevention beyond traditional risk management, while CHAMPION-AF shows that even compelling interventions still need to earn their place through outcomes data.
For ATTR-CM, the Wainua result is especially clarifying. Rather than opening a new combination-therapy chapter, it has cemented Attruby as the favoured option in ATTR-CM treatment and reinforced the wider role of stabilizers as the backbone of care. In a crowded cardiology pipeline, that matters because the therapies most likely to change practice are not necessarily the newest, but the ones that keep proving they deserve clinicians’ confidence.
